Jen Smith

Freelance Writer at Freelance

Recovering sportswriter. Journalism professor at the University of Kentucky. Mom. Wife. Lucky girl.

Featured in: Favicon

dailymail.co.uk Favicon

cbsnews.com Favicon

insider.com Favicon

investopedia.com Favicon

flipboard.com Favicon

miamiherald.com Favicon

huffingtonpost.co.uk Favicon

audioboom.com + 116 more

Articles

Gastrointestinal Cancer Highlights From ASCO 2025

3 days ago | cancertherapyadvisor.com | Jen Smith

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances that may inform the treatment of gastrointestinal cancer.1-8 Read on for more details on these studies. Results from the phase 3 MATTERHORN trial support perioperative durvalumab plus FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) as a new standard of care for patients with localized gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to Yelena Y.
Northern US states try to woo travelers with ‘Canadians-only’ deals amid faltering cross-border tourism

1 week ago | aol.com | Jen Smith

Like maple syrup and lakeside lounging, an annual influx of Canadians tourists has long been a part of life for the border-hugging New York region known as “North Country.”“I don’t ever remember a summer where I wasn’t at the beach, hearing the French language and seeing Quebec license plates,” said Kristy Kennedy, who grew up in the area.
Lurbinectedin-Atezolizumab Maintenance: A New Standard for ES-SCLC?

2 weeks ago | shorturl.at | Jen Smith

Adding lurbinectedin to atezolizumab as first-line maintenance improved progression-free survival (PFS) and overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the phase 3 IMforte trial.1,2“Given the results, we believe that there is potential for lurbinectedin plus atezo to be a standard of care in this setting,” said Luis G.
How Can Cancer Apps Help Patients and Providers?

2 weeks ago | pulmonologyadvisor.com | Jen Smith |Mark L. Fuerst |Julie Ehlers |Rachelle R. Ramsey

Cancer apps — smartphone applications targeted to cancer patients — can be helpful tools, keeping patients informed about their disease, helping them track their medications and symptoms, and facilitating connections with health care providers and other patients.1-3 Experts note, however, that cancer apps have limitations and may even be detrimental in certain cases.
Adding Perioperative Systemic Therapy to CRS-HIPEC Improves PFS, Not OS

2 weeks ago | gastroenterologyadvisor.com | Jen Smith

Adding perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can improve some outcomes in patients with resectable colorectal peritoneal metastases, according to research presented at the ASCO Annual Meeting 2025. This phase 3 trial — CAIRO6 (NCT02758951) — showed that perioperative systemic therapy improved progression-free survival (PFS) and disease-free survival (DFS) but not overall survival (OS).
Most Americans Surveyed Do Not Support Trump’s Cuts to Federal Health Agencies

3 weeks ago | hematologyadvisor.com | Jen Smith

Most Americans surveyed said they do not support the Trump administration’s recent cuts to staff and spending at federal health agencies. The survey was conducted by KFF and included a nationally representative sample of 1380 US adults. Overall, 61% of survey respondents said they oppose major cuts to spending and staff at federal health agencies.
Adding Perioperative Systemic Therapy to CRS-HIPEC Improves PFS, Not OS

4 weeks ago | shorturl.at | Jen Smith

Adding perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can improve some outcomes in patients with resectable colorectal peritoneal metastases, according to research presented at the ASCO Annual Meeting 2025. This phase 3 trial — CAIRO6 (NCT02758951) — showed that perioperative systemic therapy improved progression-free survival (PFS) and disease-free survival (DFS) but not overall survival (OS).
Novel MCED Test May Detect Multiple Cancer Types in High-Risk Patients

4 weeks ago | shorturl.at | Jen Smith

A novel multi-cancer early detection (MCED) test can detect multiple cancer types in patients with obesity, including cancers for which no screening programs currently exist, according to research presented at the ASCO Annual Meeting 2025. The MCED test, which is being developed by Harbinger Health, uses methylation patterns of cell-free circulating tumor DNA (ctDNA) in the blood to detect cancer. The reflex test system employs a 2-step approach.
Adding Perioperative Systemic Therapy to CRS-HIPEC Improves PFS, Not OS

4 weeks ago | cancertherapyadvisor.com | Jen Smith

Adding perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) can improve some outcomes in patients with resectable colorectal peritoneal metastases, according to research presented at the ASCO Annual Meeting 2025. This phase 3 trial — CAIRO6 (NCT02758951) — showed that perioperative systemic therapy improved progression-free survival (PFS) and disease-free survival (DFS) but not overall survival (OS).
Combo Deemed New Standard of Care for BRAF-Mutant, Metastatic Colorectal Cancer

4 weeks ago | shorturl.at | Jen Smith

Encorafenib plus cetuximab and mFOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) outperformed standard first-line treatment in a phase 3 trial of patients with BRAF V600E-mutated, metastatic colorectal cancer, according to results presented at the ASCO Annual Meeting 2025.1In this trial — BREAKWATER (NCT04607421) — encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival (PFS) and overall survival (OS) when compared to standard chemotherapy.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 9K
Tweets: 52K
DMs Open: No

No Tweets found.